OncoSil Medical Limited

OSL

AU000000OSL3

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 07:10:36 15/05/2024 BST			5-day change	1st Jan Change
0.005 ^AUD	+11.11%		+11.11%	-44.44%

05-02	OncoSil Medical Raises AU$5.3 Million under Entitlement Offer	MT
04-18	OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial	MT

Oncosil Medical Limited Announces Change of Principal Place of Business

August 16, 2023 at 08:44 am

The Board of OncoSil Medical Ltd. announced that Company's principal place of business has changed to Level 5, 7 Eden Park Drive, Macquarie Park NSW, 2113 with immediate effect. Email: info@oncosil.com. Telephone: + 61 2 8935 9629.

Latest news about OncoSil Medical Limited

OncoSil Medical Raises AU$5.3 Million under Entitlement Offer	05-02	MT
OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial	04-17	MT
OncoSil Medical Treats First Commercial Patient in Turkey with Implantable Pancreatic Cancer Device	04-16	MT
OncoSil Medical Treats First UK Patient for Pancreatic Cancer Study	04-12	MT
OncoSil Medical Obtains Device Reimbursement Approval in UK	04-09	MT
First Austria-Based Patients Treated Using OncoSil Pancreatic Cancer Device	04-04	MT
Oncosil Medical Issues Non-Renounceable Entitlement Offer Prospectus	03-25	MT
Oncosil Medical to Raise Over AU$7 Million via Placement, Entitlement Offer	03-20	MT
OncoSil Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Australian Shares End Eight-Day Winning Streak as Early US Fed Rate Cut Hopes Fade	02-01	MT
OncoSil Device Included in German Funding Program Negotiations; Shares Jump 14%	02-01	MT
OncoSil Strikes Exclusive Distribution Deal For Turkish Market; Shares Jump 14%	02-01	MT
OncoSil Medical Receives AU$1.1 Million R&D Tax Rebate	12-15	MT
First Patient Treated in OncoSil Medical's Pancreatic Cancer Drug Trial	11-29	MT
Oncosil Medical Limited Elects Gabrielle Liberatore as Director	11-29	CI
Australian Shares Rise on Expectations of Easing October CPI	11-24	MT
OncoSil Medical Secures Insurer Clearance for Pancreatic Cancer Device in Israel	11-24	MT
OncoSil Medical Limited Announces Retirement of Brian Leedman from the Board	18/09/23	CI
OncoSil Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23	CI
Oncosil Medical Limited Announces Change of Principal Place of Business	16/08/23	CI
OncoSil Medical Limited Appoints Doug Cubbin as Director	09/08/23	CI
Oncosil Medical Appoints Incoming Chair	07/08/23	MT
OncoSil Appoints Gabriel Liberatore to the Board	14/07/23	CI
Genetic Signatures Appoints CFO/COO	16/06/23	MT
OncoSil Medical Secures Ethics Approval for Pancreatic Cancer Trial	05/06/23	MT

Chart OncoSil Medical Limited

Duration

Period

More charts

Company Profile

OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ONCOSIL MEDICAL LIMITED	-44.44%	8.96M
NOVO NORDISK A/S	+31.31%	588B
JOHNSON & JOHNSON	-3.42%	364B
MERCK & CO., INC.	+18.02%	326B
ABBVIE INC.	+4.27%	285B
ASTRAZENECA PLC	+15.55%	239B
NOVARTIS AG	+10.11%	210B
ROCHE HOLDING AG	-7.36%	200B
AMGEN INC.	+8.12%	167B
PFIZER, INC.	-1.42%	161B

Other Pharmaceuticals